AVEO Pharmaceuticals — Investor Presentation (February 2019)
34 slides from AVEO Pharmaceuticals's investor presentation, Feb 15, 2019

Slide 1: AVEO Overview February 2019
AVEO Overview February 2019 Exhibit 99.1

Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements. The words “anticipate

Slide 3: AVEO Oncology: Strategy for Value Creation
AVEO Oncology: Strategy for Value Creation Deep Pipeline Multiple oncology and non-oncology pipeline opportunities Meaningful Market Opportunity Better tolerated single agents/combinations are the next stage of evolution Three Pillar Clinical & Regulatory Strategy EU approved, US NDA plan, IO combin

Slide 4: Multiple Potential Opportunities for Value Creation
Multiple Potential Opportunities for Value Creation Oncology Preclinical Phase 1 Phase 2 Phase 3 Regulatory Filing Marketed Partner Tivozanib VEGFR 123 TKI Ficlatuzumab HGF MAb AV-203 (CAN017) ERBB3 MAb TIVO-1 (Phase 3 Registration Study in 1st Line RCC) TIVO-3 (Phase 3 Registration Study in 3rd Lin

Slide 5: Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor
Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor Potent, selective inhibitor of VEGFRs 1, 2 and 3 with a long half-life that is designed to optimize blockade while minimizing off-target toxicities1,2 1 Nakamura K et al. Cancer Res 2006;66:9134–9142. 2 Eskens FA et al. Clin Cancer Res 2011;17:71

Slide 6: FOTIVDA (tivozanib) TIVO-3 Pivotal Phase Study
FOTIVDA® (tivozanib) TIVO-3 Pivotal Phase 3 Study

Slide 7: TIVO-3: Study Design
TIVO-3: Study Design N = 350 F Recurrent/metastatic RCC Failed at least two prior regimens including VEGFR-TKI Stratified by prior regimen (TKI-TKI; TKI-PD1; TKI-Other) ECOG PS 0 or 1 RANDOMIZE 1:1 tivozanib sorafenib 1O: PFS 2O: OS, ORR, DoR, Safety and Tolerability for ITT 60% 3rd line patients, 4

Slide 8: Primary Endpoint: Progression-Free Survival per IRC (ITT)
Primary Endpoint: Progression-Free Survival per IRC (ITT) Median PFS, mo (95% CI) Tivozanib 5.6 (5.3, 7.3) Sorafenib 3.9 (3.7, 5.6) HR, 0.73 (95% CI: 0.56, 0.94) P=0.0165 2yr PFS 18% 5% 28% 1yr PFS 11% 44% improvement in median PFS 26% risk reduction for progression or death

Slide 9: Subgroup Progression-Free Survival per IRC (Prior IO Subgroup)
Subgroup Progression-Free Survival per IRC (Prior IO Subgroup - 26% of ITT) Median PFS, mo (95% CI) Tivozanib 7.3 (5.3, 11.1) Sorafenib 5.1 (3.6, 7.4) HR, 0.55 (95% CI: 0.32, 0.94) P=0.028 35% 1yr PFS 4% 2yr PFS 25% 43% improvement in median PFS 45% risk reduction for progression or death

Slide 10: Secondary Endpoints
Secondary Endpoints Preliminary analysis (HR=1.12) represents approx. half of potential OS events 43 patients remain on study therapy (34 tivozanib vs 9 sorafenib) Interim OS analysis: Planned for August 2019 Preliminary Analysis - OS Not Mature at Time of Final PFS Analysis Final Analysis - Superio

Slide 11: Treatment-Related Adverse Events
Treatment-Related Adverse Events (≥20% frequency in either arm) Tivozanib (N=173)^ Sorafenib (N=170)^ Preferred Term, % All Grades Grade 3/4 All Grades Grade 3/4 Treatment Related AEs 84 44 94 55 Hypertension 36 20 25 14 Diarrhea 33 2 50 9 Fatigue 29 4 19 5 Decreased Appetite 26 4 21 2 Dysphonia 24

Slide 12: The Conundrum: What Is Causing the PFS/OS Discordance?
The Conundrum: What Is Causing the PFS/OS Discordance? Is there a safety issue with tivozanib? Is there an imbalance in the study? Are the preliminary OS data too immature to reflect potential long term differences? Final PFS Preliminary OS

Slide 13: Is There a Safety Issue with Tivozanib?
Is There a Safety Issue with Tivozanib?

Slide 14: Safety and Exposure Data: No Apparent Safety Signal
Tivozanib (N=173)^ Sorafenib (N=170)^ Mean Number of Cycles Initiated 10.3 6.3 AEs Leading to Dose Reductions, % 24 38 AEs Leading to Dose Interruption, % 48 63 Treatment Related SAEs, % 11 10 Treatment Related Deaths, % 0 0 Deaths within 30 days of Tx, N 15 12 Exposure Adj Deaths per Month of Tx* 0

Slide 15: Extended Exposure to Tivozanib Does Not Appear to Adversely Impact OS
Data Demonstrate That Extended Exposure to Tivozanib Does not Appear to Adversely Impact OS Tivozanib correlation (R2=0.6) relative to sorafenib (R2=0.2), suggests that increased exposure to tivozanib may be more associated with OS benefit

Slide 16: Is There an Imbalance in the Study?
Is There an Imbalance in the Study?

Slide 17: Preliminary Subsequent Therapy Rates and CPI Therapy Higher for Sorafenib
Preliminary Subsequent Therapy Rates and CPI Therapy Higher for Sorafenib: Potential to Balance Over Time Treatment, N (%) Tivozanib (N=175) Sorafenib (N=175) Remain on Study Treatment* 34 (19) 9 (5) Unknown Subsequent Therapy 37 (27) 64 (37) No Subsequent Therapy 23 (13) 20 (11) Any Subsequent Ther

Slide 18: Are the OS Data Too Immature?
Are the OS Data Too Immature?

Slide 19: Preliminary OS Analysis Enriched with Patients with Minimal PFS Benefit
Preliminary OS Analysis is Enriched with Patients Who Realized Minimal PFS Benefit 2yr PFS 18% 5% 28% 1yr PFS 11% TIVO-3 PFS Curve (ITT) 72% of OS events in preliminary analysis from patients with <4 months of PFS

Slide 20: TIVO-3 Conclusions
TIVO-3 Conclusions Tivozanib significantly improves PFS and ORR compared to sorafenib in patients with treatment-refractory advanced RCC Tivozanib was superior in patients previously treated with checkpoint inhibitors as well as two VEGFR-TKIs Responses with tivozanib were more durable than sorafeni

Slide 21: Significant Potential Commercial Opportunity for Tivozanib in the United States
If Approved, Significant Potential Commercial Opportunity for Tivozanib in the United States 1st Line Market ~$1.3B1 2nd Line Market ~$900M1 3rd Line+ Market ~$300M1 Expanding opportunity Potential to be first agent indicated for 3rd & 4th line Only pivotal dataset in RCC stratified by prior PD-1 NA

Slide 22: Potential Relevance of Tivozanib in Refractory RCC
Potential Relevance of Tivozanib in Refractory RCC Source: AVEO blinded US Oncologist Market Research using approximate TIVO-3 PFS and AE profile - Dec 2018 n=100 Treatments with proven efficacy are needed for patients who have failed 2 or more lines of treatment for RCC I prefer using drugs that do

Slide 23: PD-1 Combination Opportunities
PD-1 Combination Opportunities

Slide 24: Tivozanib High Selectivity May Be a Significant Advantage
Tivozanib High Selectivity1 May Be a Significant Advantage ASCO 2017 – GU Oral Discussion2 Confidential 1 Nakamura K et al. Cancer Res 2006;66:9134–9142. 2 Hammers, Emerging VEGF-I/O Combinations: Efficacy and Toxicity, ASCO 2017

Slide 25: Tivozanib Immunomodulatory Properties: Regulatory T Cell Reduction
Tivozanib has Immunomodulatory Properties: Regulatory T Cell Reduction May Enhance PD-1 Activity Pawlowski N et al. AACR 2013. Poster 3971. Regulatory T cells suppress or downregulate induction and proliferation of effector T cells (e.g. CD4 and CD8) P=0.034

Slide 26: Demonstrated Favorable Safety
Demonstrated Favorable Safety 60% of patients experienced treatment related grade 3/4 adverse event Excluding uncomplicated hypertension, only 44% of patients experienced grade 3/4 adverse event Minimal off-target AEs observed, likely due to high specificity of tivozanib Barthelemy et al. ESMO 2018

Slide 27: Demonstrated Encouraging Preliminary Efficacy
Demonstrated Encouraging Preliminary Efficacy 56% ORR and 96% DCR 72% had tumor shrinkage ≥25% so far 4% of patients had a complete response 52% (13/25) of pts remain on therapy Results suggest additive or synergistic efficacy for tivozanib + PD1 Barthelemy et al. ESMO 2018

Slide 28: Preliminary Data for the Combination of PD-1 + VEGF TKIs
Preliminary Data for the Combination of PD-1 + VEGF TKIs: Promising Responses with Challenging Toxicity Safety (%) Tivozanib + Nivolumab1 Total N=25 Pembro + Lenvatinib4 Total N=30 Cabo^ + Nivo or IpiNivo5 GU Tumors Total N=78 (49-CN; 29-CNI) Axitinib + Pembro2 Total N=52 Axitinib + Avelumab3 Total

Slide 29: Immuno-Oncology Clinical Collaboration with AstraZeneca
Immuno-Oncology Clinical Collaboration with AstraZeneca Clinical Rationale: Potential to show enhanced efficacy and best in class tolerability profile for a TKI/IO combination with tivozanib and durvalumab Planned Ph1/2 study: costs shared equally and clinical drug supplied by each company HCC Marke

Slide 30: Partnerships, Pipeline and Financials Highlights
Partnerships, Pipeline and Financials Highlights

Slide 31: EUSA Partnership: European Launch and Milestones
Decision Resources Pharmacor Market Projections Dec 2017 https://www.onkopedia.com/de/onkopedia/guidelines/nierenzellkarzinom-hypernephrom/@@view/html/index.html EU Launch Territories: Germany, the U.K., Austria, the Netherlands and Sweden $2M milestone payment Nov 18 ~$200M Market (2017); 50% of sa

Slide 32: Ficlatuzumab, CAN017 (AV-203) and AV-380
Ficlatuzumab SCCHN: Randomized Phase 2 Trial Ongoing (Ficlatuzumab + Erbitux vs. Ficlatuzumab) Pancreatic Cancer: Phase 1/2 Trial Ongoing (Ficlatuzumab + Nab-paclitaxel + Gemcitabine) AML: Phase 1b/2 Trial Ongoing (Ficlatuzumab + High Dose Cytarabine (HiDAC) COM and other IP to at least 2027 CAN017

Slide 33: Financial Highlights
Financial Highlights $20.4M in cash, cash equivalents, and investments as of 3Q 2018 Additional $8.4 million raised through ATM sales agreement in 4Q 2018 $2M reimbursement milestone from EUSA for Germany incurred in Nov 2018 Funds planned operations into 3Q 2019* Restructured debt provides +cash fl

Slide 34: AVEO Overview February 2019
AVEO Overview February 2019
Source: SEC EDGAR · 8-K filed Feb 15, 2019
More decks from AVEO Pharmaceuticals Inc
Investor Presentation (August 2022)44 slides · Aug 9, 2022
Investor Presentation (May 2022)46 slides · May 6, 2022
Investor Presentation (March 2022)47 slides · Mar 14, 2022
Investor Presentation (July 2021)47 slides · Jul 16, 2021
Investor Presentation (July 2020)26 slides · Jul 6, 2020
Corporate Update (May 2020)25 slides · May 29, 2020